The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the SveATTR registry
Jonas Wixner, MD, PhD, Umeå University, Umeå, Sweden, discusses data from the Swedish Transthyretin Amyloidosis Registry (SveATTR) on the efficacy of diflunisal in treating hereditary transthyretin (ATTR) amyloidosis. Combined registry and trial data show that diflunisal is effective in stopping disease progression, highlighting it as an affordable treatment option for patients with variant ATTR amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
